Gait speed in clinical and daily living assessments in Parkinson’s disease patients: performance versus capacity

About
Privacy
Disclaimer

Graph Chatbot

Related publications (31)

Page 2 of 2

Re-focusing explainability in medicine

Georg Michael Joachim Starke

Using artificial intelligence to improve patient care is a cutting-edge methodology, but its implementation in clinical routine has been limited due to significant concerns about understanding its behavior. One major barrier is the explainability dilemma a ...

2022

Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies

Hilal Lashuel, Pedro José Santana Ribeiro Magalhães

Parkinson's disease (PD), the second most common progressive neurodegenerative disease, develops and progresses for 10-15 years before the clinical diagnostic symptoms of the disease are manifested. Furthermore, several aspects of PD pathology overlap with ...

NATURE PORTFOLIO2022

Fading of brain network fingerprint in Parkinson's disease predicts motor clinical impairment

Enrico Amico

The clinical connectome fingerprint (CCF) was recently introduced as a way to assess brain dynamics. It is an approach able to recognize individuals, based on the brain network. It showed its applicability providing network features used to predict the cog ...

Wiley2023

Misplaced Trust and Distrust: How Not to Engage with Medical Artificial Intelligence

Marcello Ienca

Artificial intelligence (AI) plays a rapidly increasing role in clinical care. Many of these systems, for instance, deep learning-based applications using multilayered Artificial Neural Nets, exhibit epistemic opacity in the sense that they preclude compre ...

CAMBRIDGE UNIV PRESS2022

Comparative Analysis of Total Alpha-Synuclein (alpha SYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified alpha SYN Proteoforms

Layane Hanna-el-Daher, Hilal Lashuel, Ritwik Burai, Mohamed Bilal Fares, Lorène Aeschbach

Background: The development of therapeutics for Parkinson's disease (PD) requires the establishment of biomarker assays to enable stratifying patients, monitoring disease progression, and assessing target engagement. Attempts to develop diagnostic assays b ...

IOS PRESS2022

Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensing

Andrea Ablasser

Kessler et al. identify aberrant DNA recognition by cGAS/STING and IFN-I production by inflammatory macrophages as a driver of severe ANCA-associated vasculitis. Pharmacological interventions blocking this pathway ameliorate disease and accelerate recovery ...

ROCKEFELLER UNIV PRESS2022

Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other Synucleinopathies: Gaps, Challenges, and Opportunities

Hilal Lashuel, Pedro José Santana Ribeiro Magalhães

2022

Toward an objective assessment of mobility in clinical and daily activity settings

Arash Atrsaei

Quantification of mobility is the key to monitor the progression of mobility disorders as well as the effect of an intervention. Inertial measurement units (IMUs) with dedicated algorithms can quantify postural transitions and gait as the two key aspects o ...

EPFL2021

Comparison of Laboratory and Daily-Life Gait Speed Assessment during ON and OFF States in Parkinson’s Disease

Kamiar Aminian, Arash Atrsaei

Accurate assessment of Parkinson’s disease (PD) ON and OFF states in the usual environment is essential for tailoring optimal treatments. Wearables facilitate measurements of gait in novel and unsupervised environments; however, differences between unsuper ...

2021

Toward a remote assessment of walking bout and speed: application in patients with multiple sclerosis

Kamiar Aminian, Farzin Dadashi, Benoît Mariani, Arash Atrsaei

Gait speed as a powerful biomarker of mobility is mostly assessed in controlled environments, e.g. in the clinic. With wearable inertial sensors, gait speed can be estimated in an objective manner. However, most of the previous works have validated the gai ...

2021

Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson’s Disease

Kamiar Aminian, Arash Atrsaei

In chronic disorders such as Parkinson’s disease (PD), fear of falling (FOF) is associated with falls and reduced quality of life. With inertial measurement units (IMUs) and dedicated algorithms, different aspects of mobility can be obtained during supervi ...

2021